Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-207-0202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$64.87 million
Profitability
Miscellaneous
Employees248
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) posted its quarterly earnings data on Tuesday, February, 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09. The firm earned $10.20 million during the quarter, compared to analyst estimates of $17.76 million. Akcea Therapeutics had a negative net margin of 348.13% and a negative return on equity of 90.80%. The business's quarterly revenue was down 53.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) EPS. View Akcea Therapeutics' Earnings History.
When is Akcea Therapeutics' next earnings date?
What price target have analysts set for AKCA?
6 brokerages have issued 12-month price objectives for Akcea Therapeutics' stock. Their predictions range from $31.00 to $46.00. On average, they expect Akcea Therapeutics' share price to reach $40.50 in the next year. This suggests a possible upside of 50.9% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.
Has Akcea Therapeutics been receiving favorable news coverage?
News articles about AKCA stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Nektar Therapeutics (NKTR) and Alkermes (ALKS).
What other stocks do shareholders of Akcea Therapeutics own?
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 51)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
- Ms. Sarah Boyce, Pres & Director (Age 47)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.05%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg and Paula Soteropoulos. View Institutional Ownership Trends for Akcea Therapeutics.
Which major investors are buying Akcea Therapeutics stock?
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $26.84.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $2.40 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.
What is Akcea Therapeutics' official website?
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
